Optimizing therapy early in multiple sclerosis: An evidence-based view

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 5, 2015, Pages 460-469

  Ziemssen, Tjalf ^a   De Stefano, Nicola ^b   Sormani, Maria Pia ^c   Van Wijmeersch, Bart ^d   Wiendl, Heinz ^e   Kieseier, Bernd C ^f  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d HASSELT UNIVERSITY   (Belgium)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Breakthrough disease activity; MS therapies; Optimizing treatment; Outcome measures; Switching therapy; Treatment algorithm

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELL PROTECTION; CLINICAL PRACTICE; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXPANDED DISABILITY STATUS SCALE; GASTROINTESTINAL DISEASE; HAIR DISEASE; HAIR THINNING; HEADACHE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER TOXICITY; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SYSTEMATIC REVIEW; THYROID DISEASE; WHITE MATTER; DECISION MAKING; TIME FACTOR; TREATMENT OUTCOME;

DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE SCLEROSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941619481     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.07.007     Document Type: Review

References (164)

1. M.P. Amato, B. Hakiki, B. Goretti, and et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes Neurology 78 2012 309 314
2. D.L. Arnold, R. Gold, L. Kappos, and et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study J. Neurol. 261 2014 1794 1802
3. L.J. Balcer Clinical outcome measures for research in multiple sclerosis J. Neuroophthalmol. 21 2001 296 301
4. A. Bar-Or, R. Gold, L. Kappos, and et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study J. Neurol. 260 2013 2297 2305
5. A. Bar-Or, A. Pachner, F. Menguy-Vacheron, and et al. Teriflunomide and its mechanism of action in multiple sclerosis Drugs 74 2014 659 674
6. S. Belachew, R. Phan-Ba, E. Bartholomé, and et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis Eur. J. Neurol. 18 2011 240 245
7. J.R. Berger, S.A. Houff, J. Gurwell, and et al. JC virus antibody status underestimates infection rates Ann. Neurol. 74 2013 84 90
8. N. Bergvall, N. Sfikas, P. Chin, and et al. Efficacy of fingolimod in pre-treated multiple sclerosis patients with disease activity: pooled analyses of FREEDOMS and FREEDOMS II Am. Acad. Neurol. P3 2014 174
9. R.A. Bermel, and R. Bakshi The measurement and clinical relevance of brain atrophy in multiple sclerosis Lancet Neurol. 5 2006 158 170
10. R.A. Bermel, X. You, P. Foulds, and et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β Ann. Neurol. 73 2013 95 103
11. C.J. Bevan, and B.A. Cree Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? J. Am. Med. Assoc. Neurol. 71 2014 269 270
12. Biogen Idec Ltd, Dec 2014. Tecfidera SmPC. Available at: 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002601/WC500162069.pdf〉 (accessed February 2015).
13. Biogen Idec Ltd, Dec 2014. TYSABRI SmPC. Available at: 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000603/WC500044686.pdf〉 (accessed February 2015).
14. Biogen Idec, February 2015. Personal communication.
15. G. Bloomgren, S. Richman, C. Hotermans, and et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy N. Engl. J. Med. 366 2012 1870 1880
16. R. Bomprezzi Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview Ther. Adv. Neurol. Dis. 8 2015 20 30
17. W. Brück The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage J. Neurol. 252 Suppl. 5 2005 v3 v9
18. C.B. Burness, and E.D. Deeks Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis CNS Drugs 28 2014 373 387
19. H. Butzkueven, L. Kappos, F. Pellegrini, and et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results J. Neurol. Neurosurg. Psychiatry 85 2014 1190 1197
20. L.H. Calabrese, E. Molloy, and J. Berger Sorting out the risks in progressive multifocal leukoencephalopathy Nat. Rev. Rheumatol. 11 2015 119 123
21. P.A. Calabresi, E.W. Radue, D. Goodin, and et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol. 13 2014 545 556
22. C. Caon, M. Din, W. Ching, and et al. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis Eur. J. Neurol. 13 2006 471 474
23. A. Carrá, and P. Onaha Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina Eur. J. Neurol. 15 2008 386 393
24. R.L. Carruthers, D.L. Rotstein, B.C. Healy, and et al. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy Mult. Scler. 20 2014 1381 1390
25. T. Castillo-Trivino, E.M. Mowry, A. Gajofatto, and et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy PLoS One 6 2011 e16664
26. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin. Neuropharmacol. 33 2010 91 101
27. CMEcorner.com. Clinical Insights in Neurology: Focus on Multiple Sclerosis - Issue 4. Clinical Advances in Relapsing-Remitting MS: The Role of Oral Disease-Modifying Therapies. Available at: 〈http://www.cmecorner.com/wp/clinical-insights-in-neurology-focus-on-multiple-sclerosis-issue-4〉 (accessed February 2015).
28. J.A. Cohen, F. Barkhof, G. Comi, and et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
29. J.A. Cohen, A.J. Coles, D.L. Arnold, and et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 2012 1819 1828
30. J.A. Cohen, F. Barkhof, G. Comi, and et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS J. Neurol. 260 2013 2023 2032
31. J.A. Cohen, P. von Rosenstiel, R. Gottschalk, and et al. Long-term safety of fingolimod: interim evaluation of data from the LONGTERMS trial Am. Acad. Neurol. P2 2014 210
32. A.J. Coles Alemtuzumab treatment of multiple sclerosis Semin. Neurol. 33 2013 66 73
33. A.J. Coles, C.L. Twyman, D.L. Arnold, and et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 2012 1829 1839
34. A.J. Coles, E. Fox, A. Vladic, and et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial Neurology 78 2012 1069 1078
35. A.J. Coles, D.L. Arnold, J.A. Cohen, and et al. Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study ACTRIMS-ECTRIMS 2014 P090
36. G. Comi Position and practical use of fingolimod in Europe Clin. Exp. Neuroimmunol. 5 2014 19 33
37. G. Comi, M. Filippi, F. Barkhof, and et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Lancet 357 2001 1576 1582
38. G. Comi, V. Martinelli, M. Rodegher, and et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
39. C. Confavreux, P. O'Connor, G. Comi, and et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol. 13 2014 247 256
40. J. Correale, P. Abad, R. Alvarenga, and et al. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization J. Neurol. Sci. 339 2014 196 206
41. P.K. Coyle The role of natalizumab in the treatment of multiple sclerosis Am. J. Manag. Care. 16 Suppl. 6 2010 S164 S170
42. P.K. Coyle Switching therapies in multiple sclerosis CNS Drugs 27 2013 239 247
43. N. De Stefano, A. Giorgio, M. Battaglini, and et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes Neurology 74 2010 1868 1876
44. N. De Stefano, T. Sprenger, M.S. Freedman, and et al. Including threshold rates of brain volume loss in the definition of disease activity-free in multiple sclerosis using fingolimod phase 3 data ACTRIMS-ECTRIMS 2014 P290
45. N. De Stefano, L. Airas, N. Grigoriadis, and et al. Clinical relevance of brain volume measures in multiple sclerosis CNS Drugs 28 2014 147 156
46. De Stefano, N., Stromillo, M.L., Giorgio, A., et al., 2015. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (Epub ahead of print).
47. M.S. Deloire, A. Ruet, D. Hamel, and et al. MRI predictors of cognitive outcome in early multiple sclerosis Neurology 76 2011 1161 1167
48. V. Devonshire, E. Havrdova, E.W. Radue, and et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study Lancet Neurol 11 2012 420 428
49. J.P. DiMarco, P. O'Connor, J.A. Cohen, and et al. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies Mult. Scler. Relat. Disord. 3 2014 629 638
50. R. Dobson, R.A. Rudick, B. Turner, and et al. Assessing treatment response to interferon-β: is there a role for MRI? Neurology 82 2014 248 254
51. L. Durelli, P. Barbero, M. Bergui, and et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis J. Neurol. Neurosurg. Psychiatry 79 2008 646 651
52. R. Dutta, and B.D. Trapp Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis Prog. Neurobiol. 93 2011 1 12
53. G.C. Ebers, A. Traboulsee, D. Li, and et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial J. Neurol. Neurosurg. Psychiatry 81 2010 907 912
54. O. Fernández Best practice in the use of natalizumab in multiple sclerosis Ther. Adv. Neurol. Disord. 6 2013 69 79
55. M. Filippi, and M.A. Rocca MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system J. Neurol. 252 Suppl. 5 2005 S16 S24
56. M. Filippi, M.A. Rocca, F. Barkhof, and et al. Association between pathological and MRI findings in multiple sclerosis Lancet Neurol. 11 2012 349 360
57. M. Filippi, P. Preziosa, M. Copetti, and et al. Gray matter damage predicts the accumulation of disability 13 years later in MS Neurology 81 2013 1759 1767
58. C. Ford, A.D. Goodman, K. Johnson, and et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate Mult. Scler. 16 2010 342 350
59. R.J. Fox, D.H. Miller, J.T. Phillips, and et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N. Engl. J. Med. 367 2012 1087 1097
60. R.J. Fox, D.H. Miller, J.T. Phillips, and et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N. Engl. J. Med. 367 2012 1087 1097 (Supplementary Appendix)
61. M.S. Freedman Multiple sclerosis therapeutic strategies: use second-line agents as first-line agents when time is of the essence Neurol. Clin. Pract. 1 2011 66 68
62. M.S. Freedman, D. Selchen, D.L. Arnold, and et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations Can. J. Neurol. Sci. 40 2013 307 323
63. M.S. Freedman, J.M. Kaplan, and S. Markovic-Plese Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis J. Clin. Cell Immunol. 4 2013 1000152
64. A. Gajofatto, P. Bacchetti, B. Grimes, and et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Mult. Scler. 15 2009 50 58
65. Genzyme Corporation, Oct 2014. AUBAGIO Prescribing Information. Available at: 〈http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202992s001lbl.pdf〉 (accessed February 2015).
66. Genzyme Therapeutics Ltd, March 2014. LEMTRADA SmPC. Available at: 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/003718/WC500150521.pdf〉 (accessed February 2015).
67. G. Giovannoni, S. Cook, K. Rammohan, and et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis Lancet Neurol. 10 2011 329 337
68. R. Gold, J.S. Wolinsky, M.P. Amato, and et al. Evolving expectations around early management of multiple sclerosis Ther. Adv. Neurol. Disord. 3 2010 351 367
69. R. Gold, L. Kappos, D.L. Arnold, and et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N. Engl. J. Med. 367 2012 1098 1107
70. R. Gold, G. Giovannoni, J.T. Phillips, and et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS) Mult. Scler. 21 2015 57 66
71. L. Gorelik, M. Lerner, S. Bixler, and et al. Anti-JC virus antibodies: implications for PML risk stratification Ann. Neurol. 68 2010 295 303
72. H.P. Hartung, D.L. Arnold, J.A. Cohen, and et al. Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study ACTRIMS-ECTRIMS 2014 P043
73. E. Havrdová, L. Kappos, J.A. Cohen, and et al. Clinical and magnetic resonance imaging outcomes in subgroups of patients with highly active relapsing-remitting multiple sclerosis treated with fingolimod (FTY720): results from the FREEDOMS and TRANSFORMS phase 3 studies ACTRIMS-ECTRIMS 2011 P473
74. E. Havrdová, S. Galetta, M. Hutchinson, and et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol. 8 2009 254 260
75. A. He, T. Spelman, V. Jokubaitis, and et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis J. Am. Med. Assoc. Neurol. 72 2015 405 413
76. D. Horakova, M.G. Dwyer, E. Havrdova, and et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study J. Neurol. Sci. 282 2009 112 119
77. B. Hughes, M. Cascione, M.S. Freedman, and et al. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis Mult. Scler. Relat. Disord. 3 2014 620 628
78. M. Hutchinson, R.J. Fox, D.H. Miller, and et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study J. Neurol. 260 2013 2286 2296
79. M. Hutchinson, R. Gold, R.J. Fox, and et al. Clinical efficacy of BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis according to prior therapy: an integrated analysis of the Phase 3 DEFINE and CONFIRM studies ECTRIMS 2013 P563
80. L.D. Jacobs, R.W. Beck, J.H. Simon, and et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N. Engl. J. Med. 343 2000 898 904
81. K.P. Johnson, B.R. Brooks, J.A. Cohen, and et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
82. V.G. Jokubaitis, V. Li, T. Kalincik, and et al. Fingolimod after natalizumab and the risk of short-term relapse Neurology 82 2014 1204 1211
83. T. Kalincik, D. Horakova, T. Spelman, and et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis Ann. Neurol. 77 2015 425 435
84. L. Kappos, M. Clanet, M. Sandberg-Wollheim, and et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study Neurology 65 2005 40 47
85. L. Kappos, A. Traboulsee, C. Constantinescu, and et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Neurology 67 2006 944 953
86. L. Kappos, E.W. Radue, P. O'Connor, and et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N. Engl. J. Med. 362 2010 387 401
87. L. Kappos, J. Cohen, W. Collins, and et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings Mult. Scler. Relat. Disord. 3 2014 494 504
88. O. Katrych, T.M. Simone, S. Azad, and et al. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes CNS Neurol. Disord. Drug Targets 8 2009 512 519
89. B. Khatri, F. Barkhof, G. Comi, and et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study Lancet Neurol. 10 2011 520 529
90. B.O. Khatri, J. Pelletier, L. Kappos, and et al. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS) Mult. Scler. Relat. Disord. 3 2014 355 363
91. J. Killestein, and C.H. Polman Determinants of interferon β efficacy in patients with multiple sclerosis Nat. Rev. Neurol. 7 2011 221 228
92. M. Kremenchutzky, S. Morrow, and C. Rush The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis Expert Opin. Drug Saf. 6 2007 279 288
93. A. Kutzelnigg, and H. Lassmann Pathology of multiple sclerosis and related inflammatory demyelinating diseases Handb. Clin. Neurol. 122 2014 15 58
94. A. Kutzelnigg, C.F. Lucchinetti, C. Stadelmann, and et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705 2712
95. H. Lassmann, and J. van Horssen The molecular basis of neurodegeneration in multiple sclerosis FEBS Lett. 585 2011 3715 3723
96. A.M. Lavery, L.H. Verhey, and A.T. Waldman Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials Mult. Scler. Int. 2014 262350 2014
97. T.P. Leist, M.S. Freedman, M. Benamor, and et al. Pooled safety data from four placebo-controlled teriflunomide studies Am. Acad. Neurol. P2 2014 203
98. T.P. Leist, M.S. Freedman, L. Kappos, and et al. Pooled safety analyses from the teriflunomide clinical development program ACTRIMS-ECTRIMS 2014 P097
99. E. Leray, J. Yaouanq, E. Le Page, and et al. Evidence for a two-stage disability progression in multiple sclerosis Brain 133 2010 1900 1913
100. F.D. Lublin, S.C. Reingold, J.A. Cohen, and et al. Defining the clinical course of multiple sclerosis: the 2013 revisions Neurology 83 2014 278 286
101. C.F. Lucchinetti, B.F. Popescu, R.F. Bunyan, and et al. Inflammatory cortical demyelination in early multiple sclerosis N. Engl. J. Med. 365 2011 2188 2197
102. S. Markovic-Plese, and H.F. McFarland Immunopathogenesis of the multiple sclerosis lesion Curr. Neurol. Neurosci. Rep. 1 2001 257 262
103. D. Miller, R.J. Fox, J.T. Phillips, and et al. Effects of BG-12 on magnetic resonance imaging outcomes in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a randomized, placebo-controlled, phase 3 study ENS 2012 O259
104. D.H. Miller, R.I. Grossman, S.C. Reingold, and et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis Brain 121 Pt 1 1998 3 24
105. D.H. Miller, D. Soon, K.T. Fernando, and et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS Neurology 68 2007 1390 1401
106. T. Miller, M. Habek, A.J. Coles, and et al. Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy ACTRIMS-ECTRIMS 2014 P868
107. A. Minneboo, B. Jasperse, F. Barkhof, and et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters J. Neurol. Neurosurg. Psychiatry 79 2008 917 923
108. Multiple Sclerosis Research. Barts and the London School of Medicine and Dentistry. A blog for people with MS and their families. ClinicSpeak: natalizumab PML update - Q4 2014. Available at: 〈http://multiple-sclerosis-research.blogspot.com/2015/01/clinicspeak-natalizumab-pml-update-q4.html〉 (accessed February 2015).
109. Multiple Sclerosis Society News, Oct 2014. Case of PML confirmed in someone taking Tecfidera. Available at: 〈http://www.mssociety.org.uk/ms-news/2014/10/case-pml-confirmed-someone-taking-tecfidera〉 (accessed February 2015).
110. Multiple Sclerosis Society of Canada, 19 February 2015. Case of PML reported in patient treated with Gilenya®. Available at: 〈https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya〉 (accessed February 2015).
111. Multiple Sclerosis Therapy Consensus Group (MSTCG), H. Wiendl, K.V. Toyka, and et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations J. Neurol. 255 2008 1449 1463
112. J.A. Nicholas, M.K. Racke, J. Imitola, and et al. First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks Ther. Adv. Chronic Dis. 5 2014 62 68
113. D.J. Nieuwkamp, J.L. Murk, B.W. van Oosten, and et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate N. Engl. J. Med. 372 2015 1474 1476
114. Novartis International AG. Novartis Q4 and FY 2014 condensed financial report - data. Available at: 〈http://www.novartis.com/downloads/investors/financial-results/quarterly-results/2015-01-interim-financial-report.pdf〉 (accessed February 2015).
115. Novartis Pharma GmbH, Sep 2014. GILENYA SmPC. Available at: 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002202/WC500104528.pdf〉 (accessed February 2015).
116. P. O'Connor, J.S. Wolinsky, C. Confavreux, and et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis N. Engl. J. Med. 365 2011 1293 1303
117. P. O'Connor, A. Goodman, L. Kappos, and et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study Neurology 83 2014 78 86
118. T.P. Olsson, G. Comi, M.S. Freedman, and et al. Patients free of clinical MS activity in TEMSO and TOWER: pooled analyses of two Phase 3 placebo-controlled trials Am. Acad. Neurol. P3 2014 164
119. Outteryck, O., Zephir, H., Salleron, J., et al., 2013. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler (Epub ahead of print).
120. V.C. Pereira, F.R. Malfetano, I.D. Meira, and et al. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort Arq. Neuropsiquiatr. 70 2012 774 779
121. R. Planas, R. Martin, and M. Sospedra Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life Patient Relat. Outcome Meas. 5 2014 25 33
122. C.H. Polman, P.W. O'Connor, E. Havrdova, and et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 899 910
123. V. Popescu, F. Agosta, H.E. Hulst, and et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis J. Neurol. Neurosurg. Psychiatry 84 2013 1082 1091
124. Projects in Knowledge, 2013. Chapter 2: MRI and New Imaging Technologies in Multiple Sclerosis. In: Cohen, B.A., Pelletier, D., (Eds.). Living Medical eTextbook. Neurology: Multiple Sclerosis Edition. Available at: 〈http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&i=8&jn=2023&sj=2023.02〉 (accessed February 2015).
125. L. Prosperini, V. Gallo, N. Petsas, and et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis Eur. J. Neurol. 16 2009 1202 1209
126. L. Prosperini, G. Borriello, L. De Giglio, and et al. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol. 11 2011 26
127. L. Prosperini, C. Gianni, L. Leonardi, and et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis Mult Scler 18 2012 64 71
128. L. Prosperini, M. Capobianco, and C. Giannì Identifying responders and nonresponders to interferon therapy in multiple sclerosis Degener. Neurol. Neuromuscul. Dis. 4 2014 75 84
129. N. Putzki, K. Kollia, S. Woods, and et al. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis Eur. J. Neurol. 16 2009 424 426
130. N. Putzki, O. Yaldizli, R. Bühler, and et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland Eur. Neurol 63 2010 101 106
131. N. Putzki, O. Yaldizli, M. Mäurer, and et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries Eur. J. Neurol. 17 2010 31 37
132. J. Río, C. Nos, M. Tintoré, and et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials Ann. Neurol. 52 2002 400 406
133. J. Río, J. Castilló, A. Rovira, and et al. Measures in the first year of therapy predict the response to interferon beta in MS Mult. Scler. 15 2009 848 853
134. J. Río, M. Comabella, and X. Montalban Predicting responders to therapies for multiple sclerosis Nat. Rev. Neurol. 5 2009 553 560
135. J. Río, M. Comabella, and X. Montalban Multiple sclerosis: current treatment algorithms Curr. Opin. Neurol. 24 2011 230 237
136. J. Río, M. Tintoré, J. Sastre-Garriga, and et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response Eur. J. Neurol. 19 2012 899 904
137. A.T. Reder, G.C. Ebers, A. Traboulsee, and et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS Neurology 74 2010 1877 1885
138. T. Rosenkranz, M. Novas, and C. Terborg PML in a patient with lymphocytopenia treated with dimethyl fumarate N. Engl. J. Med. 372 2015 1476 1478
139. R. Rudick, A. Goodman, L. Kappos, and et al. Six-year natalizumab safety and efficacy data from the STRATA study ECTRIMS 2013 P593
140. R.A. Rudick, W.H. Stuart, P.A. Calabresi, and et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N. Engl. J. Med. 354 2006 911 923
141. M.P. Sanfilipo, R.H. Benedict, J. Sharma, and et al. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction Neuroimage 26 2005 1068 1077
142. M. Sanford Fingolimod: a review of its use in relapsing-remitting multiple sclerosis Drugs 74 2014 1411 1433
143. Sanofi-Aventis Groupe, Nov 2014. AUBAGIO SmPC. Available at: 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002514/WC500148682.pdf〉 (accessed February 2015).
144. W. Sheremata, A.D. Brown, and K.W. Rammohan Dimethyl fumarate for treating relapsing multiple sclerosis Expert Opin. Drug Saf. 14 2015 161 170
145. A. Shirani, Y. Zhao, M.E. Karim, and et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis J. Am. Med. Assoc. 308 2012 247 256
146. A. Shirani, Y. Zhao, M.E. Karim, and et al. Interferon beta and long-term disability in multiple sclerosis J. Am. Med. Assoc. Neurol. 70 2013 651 652
147. B.A. Singer Fingolimod for the treatment of relapsing multiple sclerosis Expert Rev. Neurother. 13 2013 589 602
148. J.G. Smirniotopoulos, F.M. Murphy, E.J. Rushing, and et al. Patterns of contrast enhancement in the brain and meninges Radiographics 27 2007 525 551
149. P.S. Sorensen, C. Ross, K.M. Clemmesen, and et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191
150. M. Sormani A. Signori, and M. Stromillo Refining response to treatment as defined by the Modified Rio Score Mult. Scler. 19 2013 1246 1247
151. M. Sormani, J. Rio, M. Tintore, and et al. Scoring treatment response in patients with relapsing multiple sclerosis Mult. Scler. 5 2013 605 612
152. M.P. Sormani, and P. Bruzzi MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials Lancet Neurol. 12 2013 669 676
153. M.P. Sormani, and N. De Stefano Defining and scoring response to IFN-β in multiple sclerosis Nat. Rev. Neurol. 9 2013 504 512
154. M.P. Sormani, L. Bonzano, L. Roccatagliata, and et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach Ann. Neurol. 65 2009 268 275
155. M.P. Sormani, D.K. Li, P. Bruzzi, and et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis Neurology 77 2011 1684 1690
156. M.P. Sormani, D.L. Arnold, and N. De Stefano Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis Ann. Neurol. 75 2014 43 49
157. C.S. Tan, and I.J. Koralnik Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis Lancet Neurol. 9 2010 425 437
158. V. Tomassini, A. Paolillo, P. Russo, and et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis J. Neurol. 253 2006 287 293
159. U.S. Food and Drug Administration (FDA), 25 August 2012. Medical Review: Aubagio (teriflunomide). Available at: 〈www.accessdata.fda.gov/drugsatfda-docs/nda/2012/202992Orig1s000MedR.pdf〉 (accessed February 2015).
160. P.L. van Riel, J.S. Smolen, P. Emery, and et al. Leflunomide: a manageable safety profile J. Rheumatol. Suppl. 71 2004 21 24
161. P. Vermersch, A. Czlonkowska, L.M. Grimaldi, and et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial Mult. Scler. 20 2014 705 716
162. J.S. Wolinsky, P.A. Narayana, F. Nelson, and et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide Mult. Scler. 19 2013 1310 1319
163. T. Ziemssen, M. Diaz-Lorente, A. Fuchs, and et al. 24-month interim results of PANGAEA: A 5 year registry study evaluating long-term safety, efficacy and pharmaco-economic data of German multiple sclerosis patients on fingolimod therapy Am. Acad. Neurol. P3 2014 152
164. R. Zivadinov, E. Havrdová, N. Bergsland, and et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis Radiology 268 2013 831 841